Special Research Coverage Episodes

This week, we're sharing more from the 2023 joint ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis) and ACTRIMS (Americas Committee for Treatment and Research in Multiple Sclerosis) annual meeting. What if we could identify MS before anyone experienced any of the typical clinical symptoms? Would treating that person with a high-efficacy disease-modifying therapy prevent the clinical symptoms of MS from even developing? Those are the questions that make the study of t...

With about 9,000 MS researchers and clinicians in attendance, the 2023 combined ECTRIMS-ACTRIMS meeting in Milan was the largest MS research conference in the world. During the meeting, I had an opportunity to talk with some of the best and brightest minds in MS research and clinical practice. This is your invitation to listen in on my ECTRIMS EXTRA conversation with Dr. Jiwon Oh. Dr. Oh is a neurologist, scientist, and the Medical Director of the Barlo Multiple Sclerosis Program at St. Michae...

Last week, more than 9,000 MS research scientists and clinicians from more than 110 countries traveled to Milan to attend the largest MS research conference in the world, the 2023 joint ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis) and ACTRIMS (Americas Committee for Treatment and Research in Multiple Sclerosis) annual meeting. In keeping with a RealTalk MS tradition, just as the meeting was ending and the thousands of attendees were heading for the exits, I conn...

We've been using the same MS clinical course descriptors (relapsing-remitting, secondary progressive, and primary progressive) for almost three decades. As research has provided so much additional information and insight, is it time to update the way we describe, diagnose, and treat MS? The International Advisory Committee on Clinical Trials in Multiple Sclerosis has established a working group to explore this question. And, as a means of eliciting feedback from stakeholders around the world, a...

This special episode of RealTalk MS is sponsored by Sanofi. In this special episode of RealTalk MS, Dr. Aaron Boster walks us through everything you need to know about clinical trials. If you've ever wondered what the difference is between a Phase 1 clinical trial, a Phase 2 clinical trial, or a Phase 3 clinical trial, you're about to find out. If you're curious about how a clinical trial participant's privacy is protected, how safety is ensured, and how you can learn about clinical trials tha...

Just a couple of weeks ago, the International Progressive MS Alliance convened its fourth Scientific Congress in Vienna, Austria, bringing together nearly 200 international scientists and MS leaders, including people affected by progressive MS, to report and review the progress being made in developing new, effective treatments for progressive MS. In Part 2 of our coverage, we're taking you back inside this Scientific Congress, where you'll hear from some of the top MS researchers in the world ...

Last week, the International Progressive MS Alliance convened its fourth Scientific Congress in Vienna, Austria, bringing together nearly 200 international scientists and MS leaders, including people affected by progressive MS, to report and review the progress being made in developing new, effective treatments for progressive MS. In Part 1 of our coverage, we're taking you inside this Scientific Congress, where you'll hear from some of the top MS researchers in the world who participated in th...

Last week, the Consortium of Multiple Sclerosis Centers brought together over 2,000 neurologists, MS nurses, rehabilitation specialists, and other healthcare professionals in Aurora Colorado, for their annual conference. This week, we're taking you inside the meeting and sharing our conversations with some of the difference-makers in the MS Movement. Next week, we're traveling to Vienna, Austria to attend the International Progressive MS Alliance Scientific Congress, where we'll hear updates o...

Don't miss the second installment of our Pathways To Cures Global Summit coverage. For this unprecedented event, the National MS Society brought together the best and brightest minds in MS research, the CEOs of major MS Societies, representatives from the pharmaceutical industry, and people affected by MS to update the scientific foundation of the Pathways To Cures research roadmap and set the global MS research agenda for the next 3-5 years. In Part 2 of our coverage, we're taking you back ins...

This past week, the National MS Society hosted the Pathways To Cures Global Summit, bringing together the best and brightest minds in MS research, the CEOs of major MS Societies, representatives from the pharmaceutical industry, and people affected by MS to update the scientific foundation of the Pathways To Cures research roadmap and set the global MS research agenda for the next 3-5 years. In Part 1 of our coverage, we're taking you inside this historic meeting, where you'll hear from some of...